Technology Development for the Synthesis of S-Amlodipine Nicotinate Drug Substance

被引:0
|
作者
G. A. Kim
Zh. M. Kozlova
S. O. Pchelintsev
R. T. Savel’yanova
N. M. Berezina
I. I. Krasnyuk
机构
[1] Ministry of Public Health of the Russian Federation,All
[2] I. M. Sechenov First Moscow State Medical University,Russia Scientific Center for Safety Testing of Biologically Active Substances
[3] EcoChem-Innovations,undefined
来源
关键词
-amlodipine nicotinate; amlodipine optical isomers; nicotinic acid;
D O I
暂无
中图分类号
学科分类号
摘要
Technology for the synthesis of S-amlodipine nicotinate drug substance was developed based on an acceptable method of effective separation of the amlodipine optical isomers. A literature review suggested that the most promising methods employed 2-propanol (pure or with small additions of cosolvents) as the main solvent. However, experiments showed that the optimum solvent was DMSO. The proposed synthesis of S-amlodipine nicotinate drug substance was confirmed to be stable and reproducible. Standardization methods were developed.
引用
收藏
页码:761 / 763
页数:2
相关论文
共 50 条
  • [41] Novel bio analytical method development, validation and application for simultaneous determination of nebivolol and S-amlodipine in human plasma using ultra performance liquid chromatography-tandem mass spectrometry
    Patel, Bhargav M.
    Jangid, Arvind G.
    Suhagia, B. N.
    Desai, Nirmal
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 151 : 244 - 251
  • [42] Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
    Bong-Joon Kim
    Kyoung-Im Cho
    Hyuck Moon Kwon
    Seung-Min Choi
    Chang-Hwan Yoon
    Sang Wook Lim
    Seung-Jae Joo
    Nam Ho Lee
    Sang-Yup Lim
    Seong-Hoon Lim
    Hyo-Soo Kim
    Clinical Hypertension, 28
  • [43] Effect of combination treatment of S-amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats
    Singh, Bhagat
    Sangle, Ganesh V.
    Murugan, Jeya
    Umrani, Rinku
    Roy, Subhasis
    Kulkarni, Onkar
    Semwal, Arvind
    Unnikrishnan, M. K.
    Jain, Mukul
    DIABETOLOGY & METABOLIC SYNDROME, 2014, 6
  • [44] Effect of hydrophilic and hydrophobic polymers on permeation of S-amlodipine besylate through intercalated polymeric transdermal matrix: 3(2) designing, optimization and characterization
    Rastogi, Vaibhav
    Yadav, Pragya
    Husain, Arif
    Verma, Anurag
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2019, 45 (04) : 669 - 682
  • [45] Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
    Kim, Bong-Joon
    Cho, Kyoung-Im
    Kwon, Hyuck Moon
    Choi, Seung-Min
    Yoon, Chang-Hwan
    Lim, Sang Wook
    Joo, Seung-Jae
    Lee, Nam Ho
    Lim, Sang-Yup
    Lim, Seong-Hoon
    Kim, Hyo-Soo
    CLINICAL HYPERTENSION, 2022, 28 (01)
  • [46] DEVELOPMENT AND EVALUATION OF MATRIX PATCHES AS TRANSDERMAL DRUG DELIVERY SYSTEM FOR AMLODIPINE
    Abrar, Muhammad Asad
    Ahmad, Mahmood
    Akram, Muhammad Rouf
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (01): : 119 - 127
  • [47] DEVELOPMENT OF MULLERIAN INHIBITING SUBSTANCE AS AN ANTICANCER DRUG
    CATE, RL
    NINFA, EG
    PRATT, DJ
    MACLAUGHLIN, DT
    DONAHOE, PK
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1986, 51 : 641 - 647
  • [48] Studies on the crystallinity of a pharmaceutical development drug substance
    Byard, SJ
    Jackson, SL
    Smail, A
    Bauer, M
    Apperley, DC
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (06) : 1321 - 1335
  • [49] The PROTAC technology in drug development
    Zou, Yutian
    Ma, Danhui
    Wang, Yinyin
    CELL BIOCHEMISTRY AND FUNCTION, 2019, 37 (01) : 21 - 30
  • [50] Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy
    Sen, Selcuk
    Demir, Meral
    Yigit, Zerrin
    Uresin, Ali Yagiz
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (04) : 318 - 328